Open AccessChanges in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
Author(s) -
Laura Piccio,
Robert T. Naismith,
Kathryn Trinkaus,
Robyn S. Klein,
Becky Parks,
JeriAnne Lyons,
Anne H. Cross
Publication year - 2010
Publication title -
archives of neurology
Language(s) - English
Resource type - Journals
eISSN - 1538-3687
pISSN - 0003-9942
DOI - 10.1001/archneurol.2010.99
Subject(s) - rituximab , medicine , multiple sclerosis , immunology , cerebrospinal fluid , cxcl13 , cd20 , b cell , natalizumab , chemokine , antibody , immune system , chemokine receptor
B cells are implicated in the pathogenesis of multiple sclerosis. A beneficial effect of B-cell depletion using rituximab has been shown, but the complete mechanism of action for this drug is unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom